Company intelligence / Profile preview

Elpida Therapeutics

Los Angeles, California, United Stateselpidatx.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Elpida Therapeutics develops gene therapies targeting ultra‐rare pediatric neurological diseases. Its lead candidate, Melpida, an AAV9/AP4M1 gene therapy for SPG50, has completed Phase I/II and will enter a Phase III trial in August 2024. The company also has a preclinical program for CMT4J using an AAV9/FIG4 vector and additional pipeline assets targeting other rare CNS disorders. Elpida’s model focuses on programs deprioritized by traditional biotech due to small patient populations but with strong scientific rationale. Early results show promise in animal models and initial human studies[2][3][5][6].

Therapeutic areas
Neurology
Modalities
AAV-based gene therapy (AAV9)Antisense oligonucleotides (ASO)
Industry
Biotech
02

Drug pipeline

7 assets

MELPIDA

2

6 more assets in the full pipeline.

Request access →
03

Partnerships

Viralgen Vector Core – manufacturing partner for clinical trial material[9]Cure CMT4J Foundation – advocacy/research partnership[4]University of Texas Southwestern Medical Center – academic collaboration on Melpida development[6]California Institute for Regenerative Medicine – grant funding/collaboration[3]

Beyond the preview

Go deeper on Elpida Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elpida Therapeutics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call